This historic change in federal policy has garnered bipartisan support and highlights the growing momentum toward humane and modern scientific practices.
**Trump Administration Advances Animal Testing Reforms**
**Trump Administration Advances Animal Testing Reforms**
The FDA and EPA announce a pivotal shift away from animal testing using advanced technology.
The Trump administration has garnered unexpected, yet widespread bipartisan acclaim for its recent announcement aimed at phasing out animal testing in federal programs. This initiative, affecting the Food and Drug Administration (FDA) and the Environmental Protection Agency (EPA), marks a significant policy shift that aligns with contemporary scientific ethics and animal rights.
On Thursday, the FDA announced plans to eliminate many of its animal testing requirements related to antibody therapies and drug treatments. Instead, the agency will adopt innovative solutions such as organ-on-a-chip technologies, which replicate human biological responses without the need for live animal subjects.
Kathy Guillermo, senior vice president of PETA, a prominent animal rights organization, expressed support for the FDA’s decision. "PETA applauds the FDA’s decision to stop harming animals and adopt human-relevant testing strategies for evaluating antibody therapies," she stated. Guillermo advocated for even further actions, pleading for a complete discontinuation of primate testing funded by federal concessions while pushing for the continued integration of 21st-century scientific approaches.
Similarly, the EPA has also indicated a reduction in its reliance on animal testing, marking the Trump administration as the first to systematically initiate such reforms across various federal agencies. This unprecedented approach signifies a milestone in scientific ethics that has been positively recognized even by groups that typically do not align with Trump's administration.
By adopting these modernized methods, the administration is working towards a more humane framework for evaluating drugs and chemicals, which is a vital step forward in aligning federal practices with the ongoing advancements in science and technology.
On Thursday, the FDA announced plans to eliminate many of its animal testing requirements related to antibody therapies and drug treatments. Instead, the agency will adopt innovative solutions such as organ-on-a-chip technologies, which replicate human biological responses without the need for live animal subjects.
Kathy Guillermo, senior vice president of PETA, a prominent animal rights organization, expressed support for the FDA’s decision. "PETA applauds the FDA’s decision to stop harming animals and adopt human-relevant testing strategies for evaluating antibody therapies," she stated. Guillermo advocated for even further actions, pleading for a complete discontinuation of primate testing funded by federal concessions while pushing for the continued integration of 21st-century scientific approaches.
Similarly, the EPA has also indicated a reduction in its reliance on animal testing, marking the Trump administration as the first to systematically initiate such reforms across various federal agencies. This unprecedented approach signifies a milestone in scientific ethics that has been positively recognized even by groups that typically do not align with Trump's administration.
By adopting these modernized methods, the administration is working towards a more humane framework for evaluating drugs and chemicals, which is a vital step forward in aligning federal practices with the ongoing advancements in science and technology.
